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Laboratory of Integrative and Systems Physiology (LISP), Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, SwitzerlandBile acids (BAs) are amphipathic molecules that facilitate the absorption. The scope of this review is to provide an update on
uptake of lipids, and their levels ﬂuctuate in the intestine as well
as in the blood circulation depending on food intake. Besides
their role in dietary lipid absorption, bile acids function as signal-
ing molecules capable to activate speciﬁc receptors. These BA
receptors are not only important in the regulation of bile acid
synthesis and their metabolism, but also regulate glucose homeo-
stasis, lipid metabolism, and energy expenditure. These processes
are important in diabetes and other facets of the metabolic syn-
drome, which represents a considerable increasing health bur-
den. In addition to the function of the nuclear receptor FXRa in
regulating local effects in the organs of the enterohepatic axis,
increasing evidence points to a crucial role of the G-protein cou-
pled receptor (GPCR) TGR5 in mediating systemic actions of BAs.
Here we discuss the current knowledge on BA receptors, with a
strong focus on the cell membrane receptor TGR5, which emerges
as a valuable target for intervention in metabolic diseases.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
BAs are multifunctional in metabolism
Bile acids (BAs) are a component of bile, which also contains phos-
phatidylcholine, bilirubin, and cholesterol as main constituents.
An important physiological role of BAs is to facilitate the uptake
of lipids together with the fat-soluble vitamins A, D, E, and K from
the intestine. BAs facilitate these absorptive processes through
their detergent properties, which allow the emulsiﬁcation of lip-
ids [1]. BAs also play a major role in inﬂuencing the intestinal
microbial ﬂora, as well as in the elimination of cholesterol from
the body [2,3]. More recently, BAs are increasingly being appreci-
ated for their signaling properties to transmit information to cells
and organs concerning the fasting/feeding state thereby regulat-
ing processes ranging from bile acid and lipid metabolism to
glucose and energy homeostasis [4,5]. This is in fact not too
surprising given the central role BAs play in dietary lipidJournal of Hepatology 20
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their pharmaceutical implications to treat metabolic diseases,
such as diabetes and other risk factors of the metabolic syndrome.Signaling pathways activated by BAs
Nuclear receptor signaling pathways
FXR is a nuclear receptor that controls BA homeostasis and trans-
port as outlined (see Textboxes 1–3; [6–33]; Fig. 1). The FXR
cDNA was ﬁrst cloned from both mouse and rat in 1995
[34,35]. Rodents have two FXR family members, FXRa and FXRb.
In humans only FXRa is expressed, although FXRb is still present
in the human genome as a non-expressed pseudogene. FXRa is
most potently activated by conjugated or unconjugated forms
of CDCA with an EC50 in the range of 4.5–10 lM [36–38], while
FXRb in mice is activated by lanosterol, an intermediate of bile
acid synthesis [39].
In addition to FXRa, other nuclear receptors directly activated
by LCA are the pregnane X receptor (PXR) and the vitamin D
receptor (VDR) [40–42] (see Fig. 2). PXR is not only activated by
LCA, but also by certain bile acid precursors, such as 7a-OH-4-
cholesten-3-one [43]. PXR is like FXRa expressed in the liver
and intestine [40,41]. One of the physiological functions of PXR
is to induce phase I detoxiﬁcation metabolism through induction
of CYP3A expression, which explains the ﬁnding that PXR trans-
genic mice are protected against LCA-induced liver toxicity in a
model of cholestasis [40]. Like PXR, VDR plays a role in the detox-
iﬁcation of BAs through upregulation of CYP3A [42]. In addition
to their roles in detoxifying BAs, both nuclear receptors inhibit
BA synthesis. VDR is not expressed in hepatocytes [44]. However,
activation of VDR in the intestine by vitamin D widely inhibits BA
synthesis via the FGF19-CYP7A1 pathway [45], and activation of
PXR with rifampicin, an agonist of human PXR, inhibits BA syn-
thesis through a pathway involving HNF4a [46]. It should be
noted that relative high concentrations of LCA (ranging from 30
to 100 lM) are needed to induce activation of VDR and PXR,
which could raise questions about the physiological relevance
of the direct regulation of their activity by BAs.
Kinase-signaling pathways regulated by BAs
BAs also modulate kinase-signaling pathways, such as the JNK











Fig. 1. Simpliﬁed overview of classical bile acid synthesis pathway in mice.
CYP7A1 and CYP8B1 catalyze the ﬁrst and third reaction, respectively. Dotted
lines represent several steps in the synthesis of BAs that involve multiple
enzymes. AKR1D1 is an abbreviation for D4-3-oxosteroid 5b-reductase.
Reviewdownregulation of CYP7A1 [47]. Another study has coupled JNK
activation indirectly to BAs as the mechanism of the FGF19-
FGFR4 signaling pathway to suppress CYP7A1 [48]. In addition
to JNK, also the p38 mitogen activated protein kinases
(p38MAPK), the extracellular signal-regulated kinase (ERK) path-
way, as well as Akt are activated by BAs [49,50]. Although the
precise mechanisms involved are not fully clear, a study has indi-
cated that phosphorylation of ERK1, ERK2, and Akt by BAs is
induced through both radical oxygen species (ROS)-dependent,1264 Journal of Hepatology 2011as well as through GPCR-dependent pathways [50]. The activa-
tion of these phosphorylation cascades by BAs is, besides the sup-
pression of CYP7A1, also involved in the regulation of apoptosis
and cytoprotective effects [49,51]. It is also tempting to speculate
that some of these signaling pathways may be involved in the
enhanced lifespan, observed in yeast exposed to BAs, as yeast
do not express either the nuclear or membrane BA receptors [52].
GPCR signaling pathways modulated by BAs
Most relevant to this review is that BAs also bind andmodulate the
activity of speciﬁc G-protein coupled receptors (GPCRs) (see
Fig. 2). The total GPCR family comprises over 800 receptors, which
are divided into three subgroups [53]. There are currently three
known GPCRs whose activities are modulated by BAs. Based
on their sequence homology, these BA-modulated GPCRs are
classiﬁed in the class A or rhodopsin-like receptor class, which
represents the largest subgroup of GPCRs. BAs are able to modu-
late the activity of the muscarinic receptors (also designated as
acetylcholine receptors) [54,55], and inhibit the activity of the
formyl-peptide receptors (FPRs) [56,57]. FPR receptors have been
described to be expressed in neutrophils and monocytes, and are
activated by N-formyl groups, present on bacterial and mitochon-
drial proteins. This induces cell chemotaxis, believed to direct
phagocytes to sites of tissue damage or infections. It is possible
that the inhibition of activity of these receptors by BAs contributes
to anti-inﬂammatory properties of BAs, as CDCA inhibited FPR-
induced human leukocyte chemotaxis. [58]. The ﬁve muscarinic
receptors (designated M1–M5) regulate numerous physiological
processes by mediating parasympathetic innervation viavol. 54 j 1263–1272
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ute to several diseases, including metabolic diseases [59]. Musca-
rinic receptors are expressed in the central nervous system aswell
as in peripheral organs. For example, theM3muscarinic receptors,
which are predominantly expressed in gastrointestinal tissues,
control smooth-muscle contractility and glandular secretion. Also
the pancreatic b-islet cells express M3 muscarinic receptors, and
induce insulin release during the pre-absorptive phase of feeding
[60]. These data suggest that these receptors could potentially
contribute to a broad range of effects observed by BAs, although
it should be mentioned that high millimolar concentrations of
BAs are necessary to induce activation of muscarinic receptors.
The relevance has not been analyzed so far in humans.
The GPCR that has beenmost studied in relation to BAs is TGR5,
also known as M-BAR, GPBAR, or GPR131. This cell-surface BA
receptor was discovered in 2002 [61], and ﬁrst characterized in
2003 [62]. TGR5 is encoded by a single-exon gene, and its conser-
vation among several vertebrate species underlines the relevanceJournal of Hepatology 2011of this GPCR in vertebrate physiology [61]. Human TGR5 is acti-
vated bymultipleBAs,with LCAbeing themost potent natural ago-
nist with an EC50 of 0.53 lM [61,62]. Next to LCA, other bile acids
that activate TGR5 include conjugated and unconjugated forms
of DCA, CDCA, and CA with an EC50 of 1.0, 4.4, and 7.7 lM, respec-
tively [62]. Human andmouse TGR5 showbasically the same afﬁn-
ity for the different BAs, although certain synthetic TGR5 agonists
reveal a large difference between mouse and human TGR5 with
regard to their efﬁcacy to activate the receptor [63].
The bile acid receptor TGR5
Expression and signaling of TGR5
TGR5 is expressed in many different organs and cells with vary-
ing degrees of expression. For example, high expression levels of
TGR5 have been detected in gallbladder epithelium [64,65] and in
the intestine, mainly in the ileum and colon [61,66]. TGR5 was
also highly expressed in human monocytes as compared to other
human leukocyte subsets examined [62]. In line with these ﬁnd-
ings, rabbit spleen and rabbit alveolar macrophages were also
found to express relatively high levels of TGR5 versus other tis-
sues [62]. TGR5 is detected in several liver cells, including rat
liver sinusoidal endothelial cells, as well as in rat Kupffer cells,
resident macrophages of the liver [67,68]. TGR5 is also expressed
in BAT, skeletal muscle, and selected areas of the central nervous
system [69,70]. Furthermore, TGR5 is ubiquitously expressed in
many more different organs and cells with varying degrees of
expression [62,64].
In resting conditions, GPCRs, including TGR5, are in a so-called
low-afﬁnity state. In response to binding of BAs to the ligand-vol. 54 j 1263–1272 1265
Fig. 2. Representation of signaling pathways that are modulated by BAs. Genomic and non-genomic actions of BAs are mediated by nuclear receptors and G-protein
coupled receptors. The BAs that modulate the activity of the receptor are indicated in the arrow, and are sorted by decreasing potency (top to bottom). Arrows in green
indicate agonistic actions, red indicates antagonistic/inhibitory actions and blue indicates a modulatory effect, either agonistic or antagonistic. Receptors for which only a
limited number of BAs were tested are indicated with dashed arrows. ⁄Only conjugated forms of LCA and DCA are reported to activate the muscarinic receptors.
Reviewbinding pocket of the receptor, a complex is released from TGR5
consisting of G-protein-as, b, and c [53,62]. GDP is subsequently
released from the G-protein and replaced by GTP, leading to dis-
sociation of the G-protein complexes into G-protein-as and bc
dimers. G-protein-as subsequently activates adenylyl cyclase
resulting in the induction of cAMP and activation of protein
kinase A (PKA), which in turn induces further downstream signal-
ing [62] (see Fig. 3). Whether TGR5 may also bind to other G-pro-
teins, which have distinct downstream effector molecules, is still
an open question [53].Fig. 3. Simpliﬁed overview of the TGR5-signaling pathway leading to down-
stream signaling via cAMP induction.
1266 Journal of Hepatology 2011TGR5 in BA homeostasis and metabolism
To explore the biological role of TGR5, several groups have inde-
pendently generated TGR5/ mice [64,66,71]. Interestingly, the
total bile acid pool size in TGR5/ mice was decreased as com-
pared to that of wild-type mice [66], which was also observed
by our laboratory (JA & KS, unpublished data). The cause of the
decreased BA pool in TGR5/ mice is currently unknown, but
appears not to be caused by changed fecal excretion of BAs, which
was similar between TGR5/ and control mice [66].
In addition to changes in the BA pool size, TGR5/ mice fed a
lithogenic diet were protected against cholesterol gallstone for-
mation [72]. Hydrophobic bile salts decrease gallbladder smooth
muscle function potentially via stimulation of TGR5, which could
be a contributing factor in the manifestation of gallstone disease
[73]. Additionally, TGR5 is expressed in human gallbladder epi-
thelial cells and cholangiocytes and was shown to play a role in
bile composition, via the induction of chloride secretion [65,74].
Taken together, the physiological changes observed in mice lack-
ing TGR5 with regard to BA homeostasis, combined with the
expression of TGR5 in human tissues relevant to BA homeostasis
hint toward a role of TGR5 in bile formation and homeostasis in
man [65,74].
Effect of TGR5 on body weight
TGR5 activation induces a signiﬁcant reduction of the body
weight of mice fed a high fat diet. We ﬁrst demonstrated that die-
tary supplementation of BAs signiﬁcantly reduces body weight
gain in C57Bl/6J mice fed a high fat diet [69]. CA administrationvol. 54 j 1263–1272
Table 1. Cellular actions described for TGR5 in different cell types.
Cell type Species  Cellular action References
Macrophages* Rabbit / Rat/namuH noitcudorpenikotycfonoitibihnI [62, 68] 
Enteroendocrine cells esuoM/namuH Secretion of GLP-1 [71, 79] 
Brown adipocytes Mouse  erutidnepxeygreneniesaercnI [69] 
Sketelal muscle cells Human  erutidnepxeygreneniesaercnI [69] 
Sinusoidal endothelial cells Rat esahtnysONlailehtodnefonoitalugeR [67] 
Biliary epithelial cells esuoM noitercesedirolhcfonoitomorP [65]
Astrocytes Rat Generation of ROS [101]
Enteric neurons Mouse  ytilitomlanitsetnifonoisserppusdnaONfoesaeleR [70]
Gallbladder smooth muscle cells noitcnufllecelcsumhtoomsreddalbllagfoesaerceD [73] Mouse
⁄Macrophages include alveolar macrophages, Kupffer cells and THP-1 cells.
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mass and morphology, and reversed 120 days of diet-induced
weight gain within 30 days, without toxicity [69]. The weight
reducing effects were not due to reduced caloric intake, but were
the consequence of enhanced energy expenditure. Using deiodin-
ase 2 (D2)-deﬁcient mice, the effect of CA on energy expenditure
was shown to require the induction of deiodinase 2 (D2) through
a TGR5-cAMP-mediated pathway that was active in murine BAT
and in human skeletal muscle myoblasts. Importantly, this effect
of BAs on energy expenditure was independent of FXR, as the FXR
agonist GW4064, did not increase cAMP levels in BAT, and
increased diet-induced obesity in mice. D2 is able to increase
mitochondrial oxidative phosphorylation and energy expenditure
in brown adipose tissue and muscle via the conversion of inactive
thyroxine (T4) into active 3,5,30-tri-iodothyronine (T3), which
subsequently binds and activates the thyroid hormone receptor,
thereby inducing energy expenditure [69]. It should be men-
tioned that postprandial plasma BA levels of 15 lM are capable
of activating TGR5 [69]. The latter effects were subsequently
conﬁrmed in a study using the semi-synthetic BA, 6-ethyl-
23(S)methyl-cholic acid (6EMCA or INT-777), which acts as a
speciﬁc TGR5, but not FXR, agonist [71].
In agreement with our data, Maruyama et al. observed that
female TGR5/ mice have increased body weight [66]. The latter
effect of TGR5 was already observed in heterozygous female
mice. In agreement with this observation, female TGR5/ mice
had a higher fat content, while the lean body weight was unaf-
fected as compared to wild-type mice. Also the body composition
of the male TGR5/ mice showed a tendency toward increased
fat content [66]. Interestingly, in the TGR5/ mice line that we
have generated in our laboratory, we also observed a signiﬁcant
increase in body weight in males ([71] and KS & JA unpublished
data). These two studies are, however, in contrast to the data of
Vassileva et al. [72], which did not observe an effect on body
weight in the absence of TGR5. This difference may very well
be explained by different diets used, or by other differences in
animal experimental conditions applied in this speciﬁc study.
Furthermore, it needs to be underscored, that the mere absence
of a receptor, as in the TGR5/ mice, should not necessary trans-
late in the opposite phenotype as observed after receptor activa-
tion by exogeneous ligands.
A recent study assessed BA levels in humans with respect to
energy expenditure [75]. In this study, patients suffering fromJournal of Hepatology 2011cirrhosis displaying elevated plasma BA levels and healthy con-
trols were compared with respect to energy expenditure. It was
concluded that no correlations between BA levels and energy
expenditure exist. It should, however, be underlined that themany
symptoms observed in cirrhosis are not controlled, and more
than likely confound the study outcome. A better understanding
of the impact of BA on energy expenditure in humans will require
further studies speciﬁcally designed to address this question.
Effects of TGR5 on glucose metabolism and insulin sensitivity
High circulating levels of BAs have been linked with beneﬁcial
effects on glucose metabolism, such as improved insulin sensitiv-
ity and postprandial glycemic control [76,77]. We have demon-
strated that BAs regulate glucose homeostasis through
activation of TGR5 [78]. In agreement with the report that
TGR5 induces GLP-1 secretion in cultured mouse enteroendocrine
STC-1 cells [79], the semi-synthetic BA, 6-ethyl-23(S)methyl-cho-
lic acid (6EMCA or INT-777), which is a speciﬁc TGR5 agonist,
induces GLP-1 secretion in both STC-1 cells as well as in human
intestinal NCI-H716 cells, and contributes as such to the effects
of TGR5 in glucose homeostasis. Silencing of TGR5 in STC-1 cells
using short hairpin RNA prevented the secretion of GLP-1, illus-
trating the involvement of TGR5 in this response. Although the
mechanism underlying TGR5-induced GLP-1 secretion is not yet
completely established, stimulation of oxidative phosphorylation
may be involved in triggering this process. The resulting increase
in ATP/ADP ratio can subsequently induce membrane depolariza-
tion and Ca2+ mobilization in a way reminiscent to the cascade of
events that precedes insulin release in pancreatic b-cells [71].
Using obese and insulin resistant mouse models, we have shown
that mice with a gain-of-function of TGR5 became more glucose
tolerant, whereas TGR5/ mice showed a delayed glucose clear-
ance compared to their wild-type littermates. This effect was cor-
related with a healthier pancreatic islet phenotype, and is at least
partly explained by the tonic increase of GLP-1 secretion by TGR5
[78]. It was recently reported by Poole et al. that TGR5 is also
expressed in inhibitory motor neurons and modulates intestinal
motility [70]. This effect of TGR5 could be related to GLP-1 induc-
tion, which is also known to inhibit intestinal motility [80]. In
apparent contrast to these observations are the ﬁndings in a
recent study with independently generated TGR5/ mice, dem-
onstrating that female and male chow fed TGR5/ mice showvol. 54 j 1263–1272 1267
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improved insulin sensitivity [72]. However, it was also shown in
this study that male TGR5/ mice fed with a high fat diet display
impaired insulin sensitivity, which is in agreement with our ﬁnd-
ings. Other evidence that TGR5 activation is beneﬁcial with
regard to diabetes comes from the observation that the triterpe-
noid, oleanolic acid, a natural TGR5 agonist, also improves glu-
cose homeostasis [81].
TGR5 modulates the immune response
One of the initial studies on TGR5 concerns its role in immune
cells and has linked TGR5 to the immunomodulatory properties
of BAs [62]. This action of TGR5 is very relevant, as low-grade
inﬂammation is suggested to contribute to the development of
the metabolic syndrome [82]. TGR5 is highly expressed in mono-
cytes and macrophages, an observation derived from the ﬁnding
that TGR5 expression is present in human spleen and human
CD14+ monocytes, as well as in rabbit alveolar macrophages
[62,68]. In accordance with a report that cAMP inhibits LPS-
induced cytokine secretion [83], BAs capable of activating TGR5
were found to increase cAMP production in alveolar macrophages
[62]. In addition, BAs reduce the phagocytic activity of these cells
and inhibit LPS-induced production of several pro-inﬂammatory
cytokines such as tumor necrosis factor-a (TNF-a), Interleukin
(IL)-1a, IL-1b, IL-6, and IL-8 [62]. Human monocytic leukemia
THP-1 cells transfected with TGR5 exhibit increased cAMP pro-
duction and a reduction in LPS-induced TNF-a expression. These
effects were not observed in untransfected THP-1 cells, which
express low levels of TGR5, demonstrating that these effects of
bile acids are mediated through activation of TGR5 [62]. Further-
more, stimulation of isolated rat Kuppfer cells with taurolitho-
cholic acid (TLC) or other TGR5 agonists, such as oleanolic acid,
as well as cAMP stimulation resulted in reduced expression of
IL-1a, IL-1b, IL-6, and TNF-a following LPS treatment [68].
Although the inhibition of inﬂammation through TGR5 activation
can be considered beneﬁcial for atherosclerosis, steatosis, and
obesity, the anti-inﬂammatory action of TGR5 in macrophages
might perhaps also explain observations that obstructive cholan-
gitis is associated with enhanced susceptibility for infections due
to decreased clearance of intrabiliary bacteria [84]. Recently,
association of 22 single nucleotide polymorphisms (SNPs) within
the TGR5 genes were assessed with regard to primary sclerosing
cholangitis (PSC). A weak association of one of these SNPs,
rs11554825, was observed with PSC as well as with ulcerative
colitis, although it could not be excluded that SNPs in neighbor-
ing genes that are in linkage disequilibrium with rs11554825
are responsible for this effect [85].
TGR5 in liver function
Administration of the speciﬁc TGR5 agonist, INT-777 to high fat
diet-fed mice reduces liver steatosis and associated hepatocyte
damage, as measured by plasma liver enzymes LDH, ASAT, and
ALAT [71]. This is correlated with decreased plasma triglyceride
and nonesteriﬁed fatty acid levels. The latter is consistent with
the report by Vassileva et al. showing a pronounced hepatostea-
tosis in male TGR5/ mice fed a high fat diet for 8 weeks [72].
These data suggest that activation of TGR5 may prevent non-
alcoholic fatty liver disease (NAFLD), although the precise regula-
tory mechanisms by which TGR5 induces this effect on liver
triglycerides remains to be dissected. Although TGR5 seems not1268 Journal of Hepatology 2011expressed in hepatocytes, it is detected in many cell types of
the liver where it could directly or indirectly modulate liver func-
tion and triglyceride metabolism. TGR5 is for instance highly
expressed in Kupffer cells, which are resident liver macrophages
[68]. It has become clear that these cells, together with their pro-
inﬂammatory cytokine secretion, are critically involved in the
progression of NAFLD [86]. The anti-inﬂammatory action of
TGR5 in these cells could, therefore, contribute to the protective
effects of TGR5 on steatosis. TGR5 has also been shown to mod-
ulate microcirculation and ﬂuid secretion in the endothelial and
biliary epithelial cells of the liver [67,74]. Although the increased
energy expenditure and GLP-1 secretion following TGR5 activa-
tion may very well explain the signiﬁcant improvement in liver
steatosis, it will be challenging to examine whether any of these
other cell types in the liver contribute to the protective effects of
TGR5 activation against steatosis. Cell-type speciﬁc TGR5/
mouse models will be extremely valuable tools to address these
questions.BA signaling as a target for intervention in the metabolic
syndrome
BA signaling as target for intervention
The signiﬁcance of BAs in human triglyceride metabolism is
underlined by ﬁndings that bile-acid binding resins induce the
production of VLDL and that treatment of cholesterol gallstones
in humans with CDCA reduces hypertriglyceridemia [87–89]. In
addition to the effects of BAs on human triglyceride metabolism,
BAs are correlated to increased insulin sensitivity in humans [76].
Furthermore, patients after bariatric surgery to correct for obesity
have higher circulating levels of BAs, which are positively corre-
lated to peak GLP-1 levels [77]. The latter observation was
recently conﬁrmed in obese patients, who have a decreased post-
prandial BA response and suboptimal GLP-1 secretion in compar-
ison to normal weight subjects [90].
A few studies report on the positive effects of bile-acid binding
resins on glucose homeostasis [91–93]. The positive effects of bile
acid sequestrants on glucose homeostasis could be the conse-
quence of improved general metabolism subsequent to the elim-
ination of cholesterol. It might, however, also raise the intriguing
possibilities that bile-acid binding resins through still unknown
mechanisms trigger TGR5 activation and GLP-1 secretion, hence
contributing to the beneﬁcial effects on glucose homeostasis.
The biological properties of TGR5 described in this review (see
Table 1), mostly observed in animal models, strongly indicate
that TGR5 is linked to the beneﬁcial properties of BAs in humans.
This is underlined by the ﬁndings that the improvements of BAs
on metabolic homeostasis are among others linked to GLP-1, for
which its regulation by TGR5 is well documented [71,79]. Fur-
thermore, a recent human genetic study indicates a potential
association of TGR5 with some aspects of the metabolic syn-
drome. This study addressed the link between the single nucleo-
tide polymorphism (SNP) rs3731859 within the human TGR5
gene and the risk for type 2 diabetes [94]. Although no correlation
was found between the onset of diabetes and the investigated
SNP, nominal associations with body mass index, waist circum-
ference, intramyocellular lipids, and fasting GLP-1 levels were
identiﬁed. This interesting result warrants further studies to
explore the effect of this (and other) SNPs in the TGR5 gene invol. 54 j 1263–1272
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different populations and calls for further mechanistic studies
that address whether this SNP, located at the 50-untranslated
region, inﬂuences TGR5 expression levels.
Pharmacological targeting of TGR5
BAs bind and activate both TGR5, as well as other (nuclear) recep-
tors, among which is FXR. The binding pocket for the membrane
BA receptor TGR5 and the nuclear BA receptor FXRa is only par-
tially conserved and minor structural modiﬁcations on the ste-
roid side chain of BAs can dictate selectivity of the ligand
toward TGR5 [95,96]. This unique ligand-binding pocket of
TGR5, therefore, allows the design of receptor selective ligands,
leading to drugs that are able to target TGR5 exclusively.
TGR5 may be targeted by natural compounds as well as by
synthetic agonists. Such TGR5 agonists include natural BAs,
semi-synthetic BAs, such as 6-ethyl-23(S)methyl-cholic acid
[97], bile alcohols, and triterpenoid compounds of plant origin,
such as oleanolic acid and betulinic acid [81,98–100]. Also certain
steroid hormones potently activate TGR5 [98], an observation
that has been recently conﬁrmed [101]. Signiﬁcant progress has
also been made with the search for synthetic TGR5 agonists, as
3-aryl-4-isoxazolecarboxamides were recently identiﬁed to acti-
vate TGR5, and found to induce GLP-1 secretion in canines
[102]. Also speciﬁc 2-aryl-3-aminomethylquinones were recently
identiﬁed as TGR5 agonists and observed to induce GLP-1 secre-
tion and to improve glucose homeostasis in diet-induced obese
mice [63]. Furthermore, many drug companies have active
TGR5 programs, which have already resulted in the publication
of several patents that describe additional TGR5 compounds. Fur-
ther biological studies using these novel selective and potent syn-
thetic TGR5 agonists are clearly awaited. Studies in animal
models with tissue-speciﬁc deﬁciencies in TGR5 and this steadily
increasing battery of TGR5 agonists will result in a better under-
standing of TGR5 biology and pharmacology, and perhaps new
treatment options for different aspects of the metabolic
syndrome.
Not all that shines is gold – issues with TGR5
Recently several properties of TGR5 have been described, that
require further investigation as they could potentially underlie
some side effects. For example, in cell culture models TGR5 has
also been linked to epidermal growth factor receptor (EGFR)
and c-Jun N-terminal kinase (JNK) signaling pathways, which
modulate cell proliferation and apoptosis [103,104]. This may
suggest that TGR5 has a potential role in cancer development,
but unfortunately evidence of such an effect was only ascertained
in cultured cells and further studies in vivo are deﬁnitely required
[103,104]. TGR5 agonists, including certain steroids [98], were
also reported to stimulate the generation of reactive oxygen spe-
cies in cultured astrocytes [101]. The impact of this potential lia-
bility also requires further investigation in vivo. TGR5 activation
has been suggested to inﬂuence cardiomyocytes as the TGR5-
active bile acids tauro-CDCA and LCA activated AKT and inhibited
glycogen synthase kinase-3b in these cells [105]. In view of the
pleiotropic effects of BAs, it will be of interest to assess
these effects in TGR5/ mice. In addition to these cellular
observations, it has been reported that TGR5/ mice have
reduced pancreatitis upon direct exposure of the pancreas to high
concentrations of taurolithocholic acid 3-sulfate sodium saltJournal of Hepatology 2011(TLCS) [106]. In this study, the fact that the pancreas is exposed
to very high concentrations of TLCS, which are normally never
reached even under pathological conditions, may raise questions
about its physiological relevance. Finally, the fact that TGR5/
mice were protected against cholelithiasis [64] could imply that
TGR5 agonism predisposes to this condition; there are, however,
no data to support a negative effect of TGR5 agonists on choleli-
thiasis. It needs to be stressed that many of these potential
unwanted side effects were either observed in cultured cells or
in animal models where extremely high, non-physiological con-
centrations of BAs were used. Further detailed studies using con-
ditions closer to physiology are, therefore, necessary to evaluate
whether such effects are also relevant for the clinical setting.
Conclusions and future perspectives
The metabolic studies described above suggest that targeting
TGR5 could provide an exciting new therapeutic approach to
improve several aspects of the metabolic syndrome. Multiple
studies reveal that TGR5 has beneﬁcial effects on body weight
in high-fat diet-fed mice. In addition, TGR5 activation improves
glucose homeostasis and reduces hepatic steatosis. Also beneﬁ-
cial effects of TGR5 on macrophage-driven inﬂammation, as evi-
denced by the reduction of pro-inﬂammatory cytokines, may
contribute to a potential positive effect of TGR5 with regard to
the metabolic syndrome. These properties of TGR5 clearly sug-
gest that activation of this membrane receptor is valuable to
combat multiple aspects of the metabolic syndrome in humans.
In view of the established role of BA or BA like molecules (dafa-
chronic acids) to promote longevity in yeast [52] and in the
worm Caenorhabditis elegans [107,108], it is furthermore plausi-
ble that the various strategies to modulate BA-signaling
described in this review could increase lifespan through their
potent hormonal activities that improve metabolism and reduce
inﬂammation, two important contributors that determine
healthspan [109].
The development of several novel natural, semi-synthetic, and
synthetic TGR5 agonists is likely to further advance this receptor
as a target for the metabolic syndrome. In addition, localized or
tissue-speciﬁc gene targeting will shed light on ways to increase
the efﬁcacy and speciﬁcity of drugs that target this BA receptor.
Despite the fact that we are convinced that targeting BA signaling
pathways through TGR5 holds great promise for the treatment of
metabolic diseases, still much work needs to be done, especially
to make sure that such compounds are safe.Disclosure
Dr. Auwerx consults for Intercept pharmaceuticals, a company
that develops bile acid based therapeutics.Acknowledgments
We thank Swiss National Science Foundation, the ERC, the NIH,
Nestlé and the Ecole Polytechnique Fédérale de Lausanne for
funding. T.W.H.P. is supported by a long-term fellowship from
FEBS, L.G.N. is supported by a CONACYT fellowship, and M.N. is
supported by a fellowship from AXA. We acknowledge Charles
Thomas for instructive discussions.vol. 54 j 1263–1272 1269
Review
References
[1] Russell DW. Fifty years of advances in bile acid synthesis and metabolism. J
Lipid Res 2009;50:S120–S125.
[2] Russell DW, Setchell KD. Bile acid biosynthesis. Biochemistry
1992;31:4737–4749.
[3] Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation
of antibacterial defense in the small intestine by the nuclear bile acid
receptor. Proc Natl Acad Sci USA 2006;103:3920–3925.
[4] Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO
J 2006;25:1419–1425.
[5] Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting
bile-acid signalling for metabolic diseases. Nat Rev Drug Discov
2008;7:678–693.
[6] Russell DW. The enzymes, regulation, and genetics of bile acid synthesis.
Annu Rev Biochem 2003;72:137–174.
[7] Ishibashi S, Schwarz M, Frykman PK, Herz J, Russell DW. Disruption of
cholesterol 7alpha-hydroxylasegene inmice. I. Postnatal lethality reversedby
bile acid and vitamin supplementation. J Biol Chem 1996;271:18017–18023.
[8] Schwarz M, Lund EG, Setchell KD, Kayden HJ, Zerwekh JE, Bjorkhem I, et al.
Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid
deﬁciency is overcome by induction of oxysterol 7alpha-hydroxylase. J Biol
Chem 1996;271:18024–18031.
[9] Kwakye JB, Barnes S, Diasio RB. Identiﬁcation of bile acid coenzyme A
synthetase in rat kidney. J Lipid Res 1993;34:95–99.
[10] Falany CN, Johnson MR, Barnes S, Diasio RB. Glycine and taurine conjuga-
tion of bile acids by a single enzyme. Molecular cloning and expression of
human liver bile acid CoA: amino acid N-acyltransferase. J Biol Chem
1994;269:19375–19379.
[11] Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, et al. Mice
deleted for fatty acid transport protein 5 have defective bile acid
conjugation and are protected from obesity. Gastroenterology
2006;130:1259–1269.
[12] Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol
and fat metabolism. Annu Rev Physiol 2006;68:159–191.
[13] Bensinger SJ, Tontonoz P. Integration of metabolism and inﬂammation by
lipid-activated nuclear receptors. Nature 2008;454 (7203):470–477.
[14] Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic
reduction of oxysterols impairs LXR signaling in cultured cells and the
livers of mice. Cell Metab 2007;5:73–79.
[15] Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, et al.
Cholesterol and bile acid metabolism are impaired in mice lacking the
nuclear oxysterol receptor LXR alpha. Cell 1998;93:693–704.
[16] Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. SHP-
1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517–526.
[17] Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al.
Molecular basis for feedback regulation of bile acid synthesis by nuclear
receptors. Mol Cell 2000;6:507–515.
[18] Brendel C, Schoonjans K, Botrugno OA, Treuter E, Auwerx J. The small
heterodimer partner interacts with the liver X receptor alpha and represses
its transcriptional activity. Mol Endocrinol 2002;16:2065–2076.
[19] Stroup D, Crestani M, Chiang JY. Identiﬁcation of a bile acid response
element in the cholesterol 7 alpha-hydroxylase gene CYP7A. Am J Physiol
1997;273:G508–G517.
[20] De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M. The
negative effects of bile acids and tumor necrosis factor-alpha on the
transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to
hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile
acid synthesis mediated by nuclear receptors. J Biol Chem
2001;276:30708–30716.
[21] Zhang M, Chiang JY. Transcriptional regulation of the human sterol
12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor
4alpha in mediating bile acid repression. J Biol Chem
2001;276:41690–41699.
[22] del Castillo-Olivares A, Gil G. Alpha 1-fetoprotein transcription factor is
required for the expression of sterol 12alpha-hydroxylase, the speciﬁc
enzyme for cholic acid synthesis. Potential role in the bile acid-mediated
regulation of gene transcription. J Biol Chem 2000;275:17793–17799.
[23] Mataki C, Magnier BC, Houten SM, Annicotte JS, Argmann C, Thomas C, et al.
Compromised intestinal lipid absorption in mice with a liver-speciﬁc
deﬁciency of liver receptor homolog 1. Mol Cell Biol 2007;27:8330–8339.
[24] Lee YK, Schmidt DR, Cummins CL, Choi M, Peng L, Zhang Y, et al. Liver
receptor homolog-1 regulates bile acid homeostasis but is not essential for
feedback regulation of bile acid synthesis. Mol Endocrinol
2008;22:1345–1356.1270 Journal of Hepatology 2011[25] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al.
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate
bile acid homeostasis. Cell Metab 2005;2:217–225.
[26] Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-speciﬁc activities of
FGF19 require Klotho beta. J Biol Chem 2007;282:27277–27284.
[27] Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, et al.
Identiﬁcation of a hormonal basis for gallbladder ﬁlling. Nat Med
2006;12:1253–1255.
[28] Houten SM, Auwerx J. The enterohepatic nuclear receptors are major
regulators of the enterohepatic circulation of bile salts. Ann Med
2004;36:482–491.
[29] Schiff ER, Small NC, Dietschy JM. Characterization of the kinetics of the
passive and active transport mechanisms for bile acid absorption in the
small intestine and colon of the rat. J Clin Invest 1972;51:1351–1362.
[30] Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption
caused by mutations in the ileal sodium-dependent bile acid transporter
gene (SLC10A2). J Clin Invest 1997;99:1880–1887.
[31] Houten SM, Volle DH, Cummins CL, Mangelsdorf DJ, Auwerx J. In vivo
imaging of farnesoid X receptor activity reveals the ileum as the primary
bile acid signaling tissue. Mol Endocrinol 2007;21:1312–1323.
[32] Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters
in normal physiology and liver disease. Gastroenterology 2004;126:
322–342.
[33] Wagner M, Zollner G, Trauner M. New molecular insights into the
mechanisms of cholestasis. J Hepatol 2009;51:565–580.
[34] Seol W, Choi HS, Moore DD. Isolation of proteins that interact speciﬁcally
with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol
1995;9:72–85.
[35] Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al.
Identiﬁcation of a nuclear receptor that is activated by farnesol metabolites.
Cell 1995;81:687–693.
[36] Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al.
Identiﬁcation of a nuclear receptor for bile acids. Science 1999;284
(5418):1362–1365.
[37] Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al.
Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284
(5418):1365–1368.
[38] Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous
bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell
1999;3:543–553.
[39] Otte K, Kranz H, Kober I, Thompson P, Hoefer M, Haubold B, et al.
Identiﬁcation of farnesoid X receptor beta as a novel mammalian nuclear
receptor sensing lanosterol. Mol Cell Biol 2003;23:864–872.
[40] Xie W, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, et al.
An essential role for nuclear receptors SXR/PXR in detoxiﬁcation of
cholestatic bile acids. Proc Natl Acad Sci USA 2001;98:3375–3380.
[41] Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI,
LaTour A, et al. The nuclear receptor PXR is a lithocholic acid sensor that
protects against liver toxicity. Proc Natl Acad Sci USA 2001;98:3369–3374.
[42] Makishima M, Lu TT, Xie W, Whitﬁeld GK, Domoto H, Evans RM, et al.
Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296
(5571):1313–1316.
[43] Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL,
et al. Identiﬁcation of bile acid precursors as endogenous ligands for the
nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA
2003;100:223–228.
[44] Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, Nanci A. The
normal liver harbors the vitamin D nuclear receptor in nonparenchymal
and biliary epithelial cells. Hepatology 2003;37:1034–1042.
[45] Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA,
Mangelsdorf DJ. Regulation of bile acid synthesis by fat-soluble vitamins
A and D. J Biol Chem 2010.
[46] Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor
inhibition of human cholesterol 7 alpha-hydroxylase gene transcription.
Am J Physiol Gastrointest Liver Physiol 2005;288:G74–G84.
[47] Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol
7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat
hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol
Chem 2001;276:15816–15822.
[48] Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Deﬁnition of a
novel growth factor-dependent signal cascade for the suppression of bile
acid biosynthesis. Genes Dev 2003;17:1581–1591.
[49] Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-
activated protein kinases in deoxycholic acid-induced apoptosis. Carcino-
genesis 2001;22:35–41.vol. 54 j 1263–1272
JOURNAL OF HEPATOLOGY
[50] Dent P, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, et al. Conjugated bile
acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive
mechanism in murine and human hepatocytes. Hepatology
2005;42:1291–1299.
[51] Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, et al. Bile acid regulation of
C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated
kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic
response of hepatocytes. Mol Cell Biol 2003;23:3052–3066.
[52] Goldberg AA, Richard VR, Kyryakov P, Bourque SD, Beach A, Burstein MT,
et al. Chemical genetic screen identiﬁes lithocholic acid as an anti-aging
compound that extends yeast chronological life span in a TOR-independent
manner, by modulating housekeeping longevity assurance processes. Aging
(Albany NY) 2010;2:393–414.
[53] Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat
Rev Mol Cell Biol 2002;3:639–650.
[54] Raufman JP, Zimniak P, Bartoszko-Malik A. Lithocholyltaurine interacts
with cholinergic receptors on dispersed chief cells from guinea pig
stomach. Am J Physiol 1998;274:G997–G1004.
[55] Raufman JP, Chen Y, Zimniak P, Cheng K. Deoxycholic acid conjugates are
muscarinic cholinergic receptor antagonists. Pharmacology
2002;65:215–221.
[56] Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends
Immunol 2002;23:541–548.
[57] Ferrari C, Macchiarulo A, Costantino G, Pellicciari R. Pharmacophore model
for bile acids recognition by the FPR receptor. J Comput Aided Mol Des
2006;20:295–303.
[58] Chen X, Yang D, Shen W, Dong HF, Wang JM, Oppenheim JJ, et al.
Characterization of chenodeoxycholic acid as an endogenous antagonist
of the G-coupled formyl peptide receptors. Inﬂamm Res 2000;49:
744–755.
[59] Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant
mice provide new insights for drug development. Nat Rev Drug Discov
2007;6:721–733.
[60] Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, et al. A critical role for beta
cell M3 muscarinic acetylcholine receptors in regulating insulin release and
blood glucose homeostasis in vivo. Cell Metab 2006;3:449–461.
[61] Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E,
et al. Identiﬁcation of membrane-type receptor for bile acids (M-BAR).
Biochem Biophys Res Commun 2002;298:714–719.
[62] Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G
protein-coupled receptor responsive to bile acids. J Biol Chem
2003;278:9435–9440.
[63] Herbert MR, Siegel DL, Staszewski L, Cayanan C, Banerjee U, Dhamija S,
et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as
agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett
2010;20:5718–5721.
[64] Vassileva G, Golovko A, Markowitz L, Abbondanzo SJ, Zeng M, Yang S, et al.
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone
formation. Biochem J 2006;398:423–430.
[65] Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D. The
membrane-bound bile acid receptor TGR5 is localized in the epithelium of
human gallbladders. Hepatology 2009;50:861–870.
[66] Maruyama T, Tanaka K, Suzuki J, Miyoshi H, Harada N, Nakamura T, et al.
Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-
Bar) in mice. J Endocrinol 2006;191:197–205.
[67] Keitel V, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, et al. The G-
protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal
endothelial cells. Hepatology 2007;45:695–704.
[68] Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D. Expression and
function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys
Res Commun 2008;372:78–84.
[69] Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H,
et al. Bile acids induce energy expenditure by promoting intracellular
thyroid hormone activation. Nature 2006;439 (7075):484–489.
[70] Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, et al.
Expression and function of the bile acid receptor GpBAR1 (TGR5) in the
murine enteric nervous system. Neurogastroenterol Motil 2010.
[71] Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-
mediated bile acid sensing controls glucose homeostasis. Cell Metab
2009;10:167–177.
[72] Vassileva G, Hu W, Hoos L, Tetzloff G, Yang S, Liu L, et al. Gender-dependent
effect of Gpbar1 genetic deletion on the metabolic proﬁles of diet-induced
obese mice. J Endocrinol 2010.
[73] Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, et al.
Hydrophobic bile salts inhibit gallbladder smooth muscle function viaJournal of Hepatology 2011stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol
2010.
[74] Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor
TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol
Chem 2010;391:785–789.
[75] Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga J, Boker KH, et al. Plasma bile
acids are not associated with energy metabolism in humans. Nutr Metab
(Lond) 2010;7:73.
[76] Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, et al. Metabolic
proﬁling of the human response to a glucose challenge reveals distinct axes
of insulin sensitivity. Mol Syst Biol 2008;4:214.
[77] Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum
bile acids are higher in humans with prior gastric bypass: potential
contribution to improved glucose and lipid metabolism. Obesity (Silver
Spring) 2009;17:1671–1677.
[78] Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid
receptor TGR5-connecting nutrition and metabolism. Thyroid
2008;18:167–174.
[79] Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like
peptide-1 secretion through TGR5 in a murine enteroendocrine cell line
STC-1. Biochem Biophys Res Commun 2005;329:386–390.
[80] Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Inhibitory effect of
glucagon-like peptide-1 on small bowel motility. Fasting but not fed
motility inhibited via nitric oxide independently of insulin and somato-
statin. J Clin Invest 1998;102:764–774.
[81] Sato H, Genet C, Strehle A, Thomas C, Lobstein A, Wagner A, et al. Anti-
hyperglycemic activity of a TGR5 agonist isolated from Olea europaea.
Biochem Biophys Res Commun 2007;362:793–798.
[82] Olefsky JM, Glass CK. Macrophages, inﬂammation, and insulin resistance.
Annu Rev Physiol 2010;72:219–246.
[83] Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, et al.
Inhibition of tumor necrosis factor-alpha and interleukin-1-beta produc-
tion by beta-adrenoceptor agonists from lipopolysaccharide-stimulated
human peripheral blood mononuclear cells. Pharmacology
1997;54:144–152.
[84] Scott-Conner CE, Grogan JB. The pathophysiology of biliary obstruction and
its effect on phagocytic and immune function. J Surg Res 1994;57:316–336.
[85] Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, ElSharawy A, et al.
Mutational characterization of the bile acid receptor TGR5 in primary
sclerosing cholangitis. PLoS One 2010;5:e12403.
[86] Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging
view. J Hepatol 2009;51:212–223.
[87] Grundy SM, Ahrens Jr EH, Salen G. Interruption of the enterohepatic
circulation of bile acids in man: comparative effects of cholestyramine and
ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971;78:94–121.
[88] Nestel PJ, Poyser A. Changes in cholesterol synthesis and excretion when
cholesterol intake is increased. Metabolism 1976;25:1591–1599.
[89] Angelin B, Einarsson K, Hellstrom K. Effect of cholestyramine on bile acid
kinetics in patients with portal cirrhosis of the liver. Evidence of a
selective defect in the formation of cholic acid. Am J Dig Dis
1978;23:1115–1120.
[90] Glicksman C, Pournaras DJ, Wright M, Roberts R, Mahon D, Welbourn R,
et al. Postprandial plasma bile acid responses in normal weight and obese
subjects. Ann Clin Biochem 2010.
[91] Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al.
Prevention and treatment of obesity, insulin resistance, and diabetes by bile
acid-binding resin. Diabetes 2007;56:239–247.
[92] Yamakawa T, Takano T, Utsunomiya H, Kadonosono K, Okamura A. Effect of
colestimide therapy for glycemic control in type 2 diabetes mellitus with
hypercholesterolemia. Endocr J 2007;54:53–58.
[93] Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl
improves glycemic control and reduces LDL cholesterol in patients with
inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Diabetes Care 2008;31:1479–1484.
[94] Mussig K, Staiger H, Machicao F, Machann J, Schick F, Schafer SA, et al.
Preliminary report: genetic variation within the GPBAR1 gene is not
associated with metabolic traits in white subjects at an increased risk for
type 2 diabetes mellitus. Metabolism 2009;58:1809–1811.
[95] Pellicciari R, Sato H, Gioiello A, Costantino G, Macchiarulo A, Sadeghpour
BM, et al. Nongenomic actions of bile acids. Synthesis and preliminary
characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as
selective modulators for the G-protein coupled receptor TGR5. J Med Chem
2007;50:4265–4268.
[96] Macchiarulo A, Gioiello A, Thomas C, Massarotti A, Nuti R, Rosatelli
E, et al. Molecular ﬁeld analysis and 3D-quantitative structure–vol. 54 j 1263–1272 1271
Review
activity relationship study (MFA 3D-QSAR) unveil novel features of
bile acid recognition at TGR5. J Chem Inf Model 2008;48:1792–
1801.
[97] Pellicciari R, Gioiello A, Macchiarulo A, Thomas C, Rosatelli E, Natalini B,
et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777)
as a potent and selective agonist for the TGR5 receptor, a novel target for
diabesity. J Med Chem 2009;52:7958–7961.
[98] Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, et al.
Novel potent and selective bile acid derivatives as TGR5 agonists: biological
screening, structure–activity relationships, and molecular modeling stud-
ies. J Med Chem 2008;51:1831–1841.
[99] Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, et al.
Structure–activity relationship study of betulinic acid, a novel and selective
TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J
Med Chem 2010;53:178–190.
[100] Genet C, Schmidt C, Strehle A, Schoonjans K, Auwerx J, Saladin R, et al.
Redeﬁning the TGR5 triterpenoid binding pocket at the C-3 position.
ChemMedChem 2010;5:1983–1988.
[101] Keitel V, Gorg B, Bidmon HJ, Zemtsova I, Spomer L, Zilles K, et al. The bile
acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia
2010;58:1794–1805.
[102] Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, et al.
Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J
Med Chem 2009;52:7962–7965.1272 Journal of Hepatology 2011[103] Yang JI, Yoon JH, Myung SJ, Gwak GY, Kim W, Chung GE, et al. Bile acid-
induced TGR5-dependent c-Jun-N terminal kinase activation leads to
enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res
Commun 2007;361:156–161.
[104] Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M. Involve-
ment of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-
induced activation of epidermal growth factor receptor and mitogen-
activated protein kinases in gastric carcinoma cells. Biochem Biophys Res
Commun 2007;354:154–159.
[105] Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A, et al.
Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a
mouse model of biliary ﬁbrosis. Hepatology 2010;51:2097–2107.
[106] Perides G, Laukkarinen JM, Vassileva G, Steer ML. Biliary acute pancreatitis
in mice is mediated by the G-protein-coupled cell surface bile acid receptor
Gpbar1. Gastroenterology 2010;138:715–725.
[107] Motola DL, Cummins CL, Rottiers V, Sharma KK, Li T, Li Y, et al.
Identiﬁcation of ligands for DAF-12 that govern dauer formation and
reproduction in C. elegans. Cell 2006;124:1209–1223.
[108] Gerisch B, Rottiers V, Li D, Motola DL, Cummins CL, Lehrach H, et al. A bile
acid-like steroid modulates Caenorhabditis elegans lifespan through nuclear
receptor signaling. Proc Natl Acad Sci USA 2007;104:5014–5019.
[109] Houtkooper RH, Williams RW, Auwerx J. Metabolic networks of longevity.
Cell 2010;142:9–14.vol. 54 j 1263–1272
